MIB1 and p53 immunoreactivity in protoplasmic astrocytomas
Autor: | Melinda L. Estes, Richard A. Pravson |
---|---|
Rok vydání: | 1996 |
Předmět: |
Adult
Male Pathology medicine.medical_specialty Necrosis Adolescent Tumor suppressor gene Astrocytoma Biology Disease-Free Survival Pathology and Forensic Medicine Temporal lobe Cellular and Molecular Neuroscience Seizures medicine Humans Neoplasm Nuclear atypia Child Brain Neoplasms Antibodies Monoclonal General Medicine Middle Aged medicine.disease Immunohistochemistry Survival Analysis Protoplasmic Astrocytoma Ki-67 Antigen Neurology Child Preschool Female Neurology (clinical) Tumor Suppressor Protein p53 medicine.symptom Headaches |
Zdroj: | Pathology International. 46:862-866 |
ISSN: | 1440-1827 1320-5463 |
Popis: | Pure protoplasmic astrocytomas are a group of rarely encountered low grade astrocytic neoplasms. Relatively few studies have specifically examined this subset of tumors. A series of 18 protoplasmic astrocytomas in 14 males and four females (age range 2.5-52, mean 22 years) were studied in order to examine MIB1 (a marker of cell proliferation) and p53 (a tumor suppressor gene) immunoreactivity. All patients presented with seizures (mean duration 94 months) and three with headaches also. Eight tumors were located in the temporal lobe and six in the frontal lobe. All tumors were characterized by a proliferation of astrocytes with round nuclear contours arranged against a microcystic background. Only rare foci of mild vascular proliferation (3 tumors), rare mitotic figures (1 tumor), and mild nuclear atypia (3 tumors) were observed. Most tumors were primarily cortical in location. Necrosis was not seen in any of the tumors. MIB1 indices (number of MIB1 positive tumor cells/1000 tumor cells evaluated x 100) ranged from 0 to 4.3 (mean 0.7); in five tumors, no MIB1 staining was observed. p53 immunoreactivity was noted in 5 of 18 tumors (28%). Five patients received adjuvant radiation therapy and one adjuvant chemotherapy. At last known follow-up, 11 patients are alive with no evidence of residual tumor (mean 70 months), six patients are alive with evidence of residual tumor (mean 58 months), and one patient died of complications unrelated to the tumor (36 months) postoperatively. Based on these findings, the conclusions presented are as follows: (i) MIB1 indices are generally low in these tumors, corroborating the clinical impression of a slow growing neoplasm; and (ii) p53 immunoreactivity is observed in a minority of protoplasmic astrocytomas. |
Databáze: | OpenAIRE |
Externí odkaz: |